Demecan is committed to the nationwide supply of high-quality medical cannabis to patients in Germany. For this purpose, the company purchased the production facility of the former cannabis producer Wayland near Dresden and is building Europe's largest indoor production facility for medical cannabis in Europe.
On September 9th, the site was visited by representatives from the German Cannabis Agency of the Federal Institute for Drugs and Medical Devices (BfArM). The Demecan facility is of high interest to BfArM, as it will ensure that the domestic supply for medicinal cannabis is provided for by a domestic manufacturer.
Established in 2017, BfArM strictly monitors the cultivation of cannabis plants for medical purposes in Germany. The agency must ensure that only cannabis of highest pharmaceutical quality is delivered to pharmacies. In May 2019 DEMECAN was the only domestic company that received a license to grow and distribute medical cannabis in Germany.
Dr. Constantin von der Groeben, Managing Director and co-founder of DEMECAN: "We are delighted that the cannabis agency has visited our production facility. The purchase of the facility was an essential milestone for us in securing the supply of high quality medical cannabis for patients in Germany".
After completion of its own production facility, DEMECAN will produce medical cannabis Made in Germany as an independent supplier to ensure sufficient availability of medical cannabis for patients in Germany.